News Column

Urologix Secures Extension of Credit Facility

February 4, 2014

MINNEAPOLIS , Feb. 4, 2014 (GLOBE NEWSWIRE) -- Urologix ® , Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that it has secured an extension to June 30, 2014 of its credit facility with Silicon Valley Bank ("SVB"), the commercial banking division of SVB Financial Group . The line of credit with SVB allows borrowing by the Company of up to the lesser of $2.0 million or the defined borrowing base consisting of 80% of eligible accounts receivable. " Urologix is pleased to have the flexibility afforded by the line of credit through the end of our fiscal year," stated Greg Fluet , Chief Executive Officer. "While we have not had to draw on the line of credit over the last two years, we think it is valuable to keep it in place as we work to transform the company into a more operationally efficient entity that is well positioned to grow." The credit facility provides Urologix with access to additional working capital so the Company can continue to execute its growth strategy. The facility is secured by the Company's assets and the Company has agreed to comply with certain financial and non-financial covenants, including providing certifications, reports and notices of certain demands. Additional details regarding the amendment extending the credit facility are included in the Company's Current Report on Form 8-K dated January 30, 2014 . About Urologix Urologix, Inc. , based in Minneapolis , develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix ' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix. If you'd like more information on this topic, please contact Brian Smrdel at (763) 475-7696 or bsmrdel@urologix.com or to learn more about Urologix and its products and services, visit their website at www.urologix.com . The Urologix, Inc. logo is available at www.urologix.com/clinicians/resource-library.php . About Silicon Valley Bank Silicon Valley Bank is the premier bank for technology, life science, cleantech, venture capital, private equity and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment and international banking services to its clients worldwide through 26 U.S. offices and seven international operations. (Nasdaq:SIVB) www.svb.com . Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "estimate" or "continue" or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, the Company's future revenue and operating performance, the effect on expenses or cash balances as a result of the previously announced strategic restructuring, or the availability of borrowing under the line of credit with Silicon Valley Bank. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's Annual Report on Form 10-K for the year ended June 30, 2013 and other documents filed with the Securities and Exchange Commission. CONTACT: Urologix Investor Relations Contact Brian Smrdel (763) 475-7696 Bsmrdel@urologix.com Source: Urologix, Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: GlobeNewswire


Story Tools